<DOC>
	<DOCNO>NCT00951054</DOCNO>
	<brief_summary>The purpose study determine whether NK012 safe effective treatment advance metastatic triple negative breast cancer .</brief_summary>
	<brief_title>A Study NK012 Patients With Advanced , Metastatic Triple Negative Breast Cancer</brief_title>
	<detailed_description>This Phase II , open label , single arm , multicenter study NK012 patient locally advance non-resectable metastatic breast cancer ER-negative , PR negative HER2-negative phenotype . NK012 administer infusion 30 minute every 28 day ( Day 1 cycle ) . Patients screen UGT1A1 polymorphism prior enrollment order determine start dose .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis breast cancer locally advanced disease surgical option , stage IV disease . ERnegative PRnegative ( define less equal 10 % tumor stain ) . HER2negative define one following : 1 . 0 1+ IHC ; 2 . 2+ 3+ IHC FISH negative ( ratio &lt; 2.2 ) ; 3. FISH negative ( ratio &lt; 2.2 ) . No less one two prior chemotherapy regimen advance metastatic disease . Prior chemotherapy must include taxane either part adjuvant regimen part metastatic disease regimen . Interval last dose prior treatment enrollment study must least 4 week cytotoxic chemotherapy ( exception : 6 week nitrosoureas mitomycin C ) , 5 halflives noncytotoxic therapy ( review Medical Monitor establish start date ) , 4 week monoclonal antibody ; patient must recover acute toxicity . Measurable disease RECIST . ECOG performance status 02 . Females least 18 year age . Adequate bone marrow function define absolute neutrophil count great equal 1,500/ mm^3 platelet great equal 100,000/mm^3 . AST ( SGOT ) ALT ( SGPT ) level great 3 x institutional ULN , total bilirubin less equal 1.5 x ULN . Serum creatinine less equal 1.5 x ULN , creatinine clearance great equal 60 mL/min ( CockcroftGault formula ) patient serum creatinine level &gt; 1.5 x ULN . Able understand show willingness sign write informed consent document . Exclusion criterion : Patient Gilbert 's Syndrome . Concurrent use investigational agent . History brain metastasis spinal cord compression , unless irradiate minimum 4 week study entry stable without requirement corticosteroid &gt; 1 week . Prior exposure topoisomerase 1 inhibitor ( i.e. , irinotecan , topotecan , camptothecin ) . Concurrent serious infection require parenteral therapy . Pregnant childbearing potential use method avoid pregnancy . A negative pregnancy test ( urine serum ) must document baseline woman childbearing potential . Patients may breastfeed infant study . Significant cardiac disease include heart failure meet New York Heart Association ( NYHA ) class III IV definition , history myocardial infarction within one year study entry , uncontrolled dysrhythmias poorly control angina . History serious ventricular arrhythmia ( VT VF , great equal 3 beat row ) , QTc great equal 450 msec men 470 msec woman , LVEF le equal 40 % MUGA ECHO .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>triple negative</keyword>
	<keyword>ER-negative</keyword>
	<keyword>PR-negative</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>ER- , PR- , HER2- ( Triple Negative ) breast cancer</keyword>
</DOC>